MOR-106
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C) . MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis[1][2].
Product Specifications
CAS Number
2304625-87-2
Product Name Alternative
MOR12743; MOR03207
UNSPSC
12352203
Target
Interleukin Related; NF-κB
Related Pathways
Immunology/Inflammation; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
References & Citations
[1]Vandeghinste N, et al. Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis. J Invest Dermatol. 2018 Jul;138 (7) :1555-1563. |[2]Lauffer F, et al. IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema. J Eur Acad Dermatol Venereol. 2020 Apr;34 (4) :800-809.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
IL-17; NF-κB
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
